Tandem Diabetes Care, Inc. TNDM
NASDAQ · United States · Health Technology
$16.50+0.19 (+1.16%)
Market closed· · USD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market closed· · USD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
SAN DIEGO, October 01, 2026--Tandem Diabetes Care, Inc. (Nasdaq: TNDM), a leading insulin delivery and diabetes technology company, plans to release its third quarter 2026 results after the financial markets close on Thursday, November 5, 2026. The Company will hold a conference call and simultaneous webcast on the same day at 4:30 pm Eastern Time (1:30 pm Pacific Time), to discuss its third quarter 2026 financial and operating results.
Tandem Diabetes Care has recently launched its Tandem Mobi automated insulin delivery system in 12 countries across Europe and Israel, using Dexcom G7 continuous glucose monitoring and Control-IQ+ technology to automatically adjust insulin every 5 minutes. The international rollout of this small, iPhone-controlled pump with flexible wear options and a 200-unit cartridge broadens Tandem’s technology ecosystem for people living with diabetes outside the United States. We’ll now explore how...
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Tandem Diabetes (NASDAQ:TNDM) and the best and worst performers in the healthcare technology industry.
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.